Arcturus and CSL Seqirus terminate sa-mRNA vaccine partnership
San Diego-based Arcturus Therapeutics (Nasdaq: ARCT) has terminated its self-amplifying mRNA collaboration with CSL Seqirus through a settlement agreement,...
Read full article →Business
Systematic, data-driven science coverage · Saturday, August 8, 2026
Most Read
Business
Pfizer Q2'26: Mevrometostat, tilrekimig and sigvotatug vedotin shape pipeline outlook
Business
Gilead Q2'26: BIC/LEN nears approval as weekly HIV pipeline expands
Business
CSPC and AstraZeneca establish biologics manufacturing joint venture in China
Business
Novo Nordisk Q2'26: ZEUS failure overshadows obesity pipeline advances
Business
Mironid raises USD 46m to advance first-in-class ADPKD therapy
Business
9h agoBioMarin drops BMN 401 following unsuccessful pivotal trial
BioMarin Discontinues BMN 401 Across All Indications After Pivotal ENPP1 Trial Fails Co-Primary Endpoints
Business
10h agoShape and Rett Syndrome Research Trust advance AI-designed RNA editor for R168X mutation
Seattle-based Shape Therapeutics and the Rett Syndrome Research Trust (RSRT) announced a partnership to advance SHP-401, an investigational RNA editing gene...
Business
10h agoTarsus secures USD 125m to fund Alkeus acquisition and expand eye care pipeline
Irvine, California-based Tarsus Pharmaceuticals (Nasdaq: TARS) announced an oversubscribed USD 125 million private investment in public equity (PIPE)...
Business
11h agoReCode expands cystic fibrosis gene editing push with new CF Foundation backing and unnamed partner
Mountain View, California-based ReCode Therapeutics announced a research collaboration with an undisclosed gene editing company to develop a CFTR-correcting...
Business
11h agoBiogen closes deal for USD 1b buyout of RayThera
Biogen (Nasdaq: BIIB) has completed its acquisition of RayThera Inc., a San Diego-based small-molecule immunology company, for a total potential...
Business
12h agoLatigo raises USD 345.6m in upsized IPO backed by Nav1.8 Phase II data
Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a Thousand Oaks, California-based clinical-stage biopharmaceutical company whose lead Nav1.8 inhibitor recently...
Business
12h agoTranscenta sells CDMO assets to WuXi Bio to focus on drug pipeline
Transcenta Holding Limited (HKEX: 6628) has agreed to sell its Hangzhou contract development and manufacturing organization assets to WuXi Biologics...
Business
1d agoActimed regains full control of S-oxprenolol after five-year partnership with Faraday
UK-based Actimed Therapeutics has reacquired full global rights to S-oxprenolol (ACM-002), an anabolic-catabolic transforming agent (ACTA) small molecule,...
Business
1d agoEnsysce expands into neuroplastogenic pain with USD 77m Cy Biopharma acquisition
San Diego-based Ensysce Biosciences (Nasdaq: ENSC) has completed the acquisition of Cy Biopharma, a privately held clinical-stage company developing...
Business
1d agoTarsus builds retina franchise in USD 800 million Alkeus deal
Tarsus Pharmaceuticals (Nasdaq: TARS) has agreed to acquire Alkeus Pharmaceuticals, a privately held retinal disease biotech, for approximately USD 450...
Business
1d agoSophia Genetics expands AstraZeneca partnership with two cDX programs
Switzerland-based Sophia Genetics (Nasdaq: SOPH) has entered a multi-year global collaboration with AstraZeneca (NYSE: AZN) to develop, validate, and deploy...
Business
2d agoBMS deploys Schrödinger's agentic AI platform across drug discovery
Schrödinger (Nasdaq: SDGR) and Bristol Myers Squibb announced a strategic software agreement to deploy Bunsen, Schrödinger's agentic AI co-scientist...
Business
2d agoBraveheart Bio ups IPO pricing for USD 382.5m take-home
Braveheart Bio, Inc. (Nasdaq: BRVE), a San Francisco-based clinical-stage biopharmaceutical company developing a next-generation oral cardiac myosin...
Business
2d agoEli Lilly Q2'26: Retatrutide heads toward filing amid BLA dispute
Eli Lilly Q2 2026 earnings call, held on August 5, 2026, was dominated by the completion of the retatrutide Phase III registrational package and a contested...
Business
2d agoNovo Nordisk Q2'26: ZEUS failure overshadows obesity pipeline advances
Novo Nordisk A/S (NOVO) held its Q2 2026 earnings call on August 5, 2026, during which the Phase III failure of ziltivekimab in cardiovascular outcomes...
The AllSci Brief
Systematic R&D and deal news. Daily.